PREVALENCE OF METABOLIC SYNDROME AND ITS COMPONENTS IN MEN WITH HORMONE-NAIVE PROSTATE CANCER

Background: The metabolic syndrome (MS) is characterized by central obesity, insulin resistance, high serum glucose levels, dyslipidaemia and systemic arterial hypertension. MS is a known risk factor for breast cancer and a causal factor for cardiovascular mortality. Men with prostate cancer (PCa) h...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2010-04, Vol.30 (4), p.1509-1509
Main Authors: Di Francesco, S, Nicolai, M, Como, A, Altieri, V, Castellan, P, Campanelli, M, Tenaglia, R L
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The metabolic syndrome (MS) is characterized by central obesity, insulin resistance, high serum glucose levels, dyslipidaemia and systemic arterial hypertension. MS is a known risk factor for breast cancer and a causal factor for cardiovascular mortality. Men with prostate cancer (PCa) have higher rates of non cancer mortality than men in the general population, with some of this excess attributed to hormonal treatment. At present, there are conflicting reports as to the causal relationship between MS and PCa and there is limited literature regarding the association between MS and PCa at the initial diagnosis, without the influence of hormonal therapy. The present study aimed to evaluate the prevalence of MS and its components in men with PCa at initial diagnosis and compared it with the prevalence in age-matched controls. Patients and Methods: This was a controlled cross-sectional study. We evaluated 80 men, including 40 patients who were hormone-naive, with a histological diagnosis of prostate adenocarcinoma (group 1), and 40 age-matched controls without any history of benign or malignant prostate disease, with a normal PSA (,3 ng/ml) and absence of suspicious lesions (group 2). MS was defined according to the Adult Treatment Panel III criteria. Men were excluded from the study if they had a Karnofsky performance status (KPS) lower than 70%, disseminated disease, history of thyroid disease, liver disease or renal insufficiency, glucocorticoid use in the previous 6 months, history of any form of hypogonadism and any history of hormonal therapy or chemotherapy for PCa. Results: There was no significant difference in mean age between the two groups (65.9 c 7.57 group 1 vs. 65.05 c 6.45 group 2). Men in the group with prostate cancer had significantly higher body max index (BMI) compared with the control group (28.06 c 3.42 vs. 25.45 c 3.24). Among 80 participants, 30% of the men in the group 1 met the criteria for MS. This prevalence was significantly higher in the PCa versus the control group (32.3% vs. 15.2%). Analysis of various components of MS revealed that men of group 1 had significantly higher overall prevalence of hyperglycaemia (35% vs. 20.2%) and hypertriglyceridaemia (40% vs. 25%) compared with the group 2. There was no significant difference in the prevalence of arterial hypertension between the two groups (50.2% vs. 40.8%). Conclusion: This is the first cross-sectional study showing the higher prevalence of MS in men with PCa at in
ISSN:0250-7005